The Library
Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch
Tools
Johnstone, E. C., Yudkin, P.L., Hey, Kirsty L., Roberts, S. J., Welch, S. J., Murphy, M. F., Griffiths, S. E. and Walton, Robert T. (2004) Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics, 14 (2). pp. 83-90. ISSN 0960-314X.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: https://doi.org/10.1097/00008571-200402000-00002
Abstract
Polymorphisms in the dopamine D2 receptor (32806DRD2 C/T and 22316DRD2 A/G) and in dopamine beta hydroxylase (1368DBH A/G) have been implicated in modulation of smoking and other reward-seeking behaviours. We hypothesized that these alleles would predict the outcome of nicotine patch therapy for smoking cessation. In 1991–93, we performed a randomized controlled trial of the nicotine patch on 1686 heavy smokers (≥ 15 cigarettes/day). In 1999–2000, we contacted 1532 of the 1612 subjects still available; 767 (50%) completed a questionnaire and gave a blood sample. In the 755 cases in which DNA was successfully genotyped, we examined associations between the polymorphisms in DRD2 and DBH, and smoking cessation. At 1 week, the patch was more effective for smokers with 32806DRD2 CT/TT genotype [patch/placebo odds ratio (OR) 2.8, 95% confidence interval (CI) 1.7–4.6] than with CC (OR 1.4, 0.9–2.1; P for difference in ORs 0.04). Smokers with both 32806DRD2 CT/TT and 1368DBH GA/AA genotypes had an OR of 3.6 (2.0–6.5) compared to 1.4 (1.0–2.1) for others (P = 0.01). At 12 weeks, the ORs for these genotypic groups were 3.6 (1.7–7.8) and 1.4 (0.9–2.3), respectively (P = 0.04). There was no association between patch effectiveness and 22316DRD2 exon 8. Short-term effectiveness of the nicotine patch may be related to dopamine beta-hydroxylase and dopamine D2 receptor genotype. Our results support the need for further investigation into personalized therapies for smoking cessation based on individual genotype.
Item Type: | Journal Article | ||||||
---|---|---|---|---|---|---|---|
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Population, Evidence & Technologies (PET) Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||||
Journal or Publication Title: | Pharmacogenetics | ||||||
Publisher: | Lippincott Williams & Wilkins | ||||||
ISSN: | 0960-314X | ||||||
Official Date: | February 2004 | ||||||
Dates: |
|
||||||
Volume: | 14 | ||||||
Number: | 2 | ||||||
Page Range: | pp. 83-90 | ||||||
Status: | Peer Reviewed | ||||||
Publication Status: | Published | ||||||
Reuse Statement (publisher, data, author rights): | cited By 120 | ||||||
Access rights to Published version: | Open Access (Creative Commons) |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |